Cardiovascular diseases have been considered as the one of the leading causes of mortality in worldwide populations, with heart attacks and strokes being acute cardiovascular events. Life after first heart attack can’t be the same as before but there are several clinical as well as lifestyle interventions to make the lives of affected patients productive. This intensifies the need for better prediction methods for these cardiovascular events in secondary prevention. While there are several methods of identifying the conventional risk factors, efforts are ongoing for introducing more biomarkers for cardiovascular risk stratification in the public healthcare industry. Researchers at the Baker Heart and Diabetes Institute have developed a novel blood test that improved upon traditional risk factors to predict the second heart attack or successive strokes in affected patients.
Large Scale Study assesses role of Lipidomic Profiling in Cardiovascular Risk Stratification
The biomarker is based on plasma lipidomic profiles and the study looked at 342 individual lipid species collected from across 10,000 samples. The results of the lipidomic profiling was tested on the sub-cohort to find the effectiveness of the biomarker in predicting future cardiovascular events and even the risk of mortality.
According to one of the researchers, the test is expected to be trialed in Australia over the next few years and eventually can be used by general practioner in identifying heart patients who are at increased risk of future strokes or other cardiovascular events.
Test to help in Secondary Prevention of Strokes and Heart Attacks
The role of plasma lipid species to stratify high-risk populations for cardiovascular events has been analyzed in several longitudinal studies before. However, few of these focused on secondary prevention of heart attacks. For instance, a similar biomarker has been trialed in the U.S. but the test included only two lipid markers. According to the researchers, the test they developed had up to ten lipid biomarkers, which is a technological advancement of sorts.
The scientists believe that the biomarker will be akin to a cholesterol test and it will be possible to conduct the test outside of hospital settings. In the coming years, the biomarkers in combination with others can be helpful in predicting diabetes and the Alzheimer’s disease.